Pfizer Inc. announced on October 7, 2026, that the U.S. Food and Drug Administration (FDA) approved TUKYSA, in combination with trastuzumab and pertuzumab, for maintenance treatment of adults with a certain type of HER2-positive metastatic breast cancer. The approval adds a chemotherapy-free option in the front-line setting that may delay disease progression.
At the European Society for Medical Oncology (ESMO) 2026 conference, Pfizer and partner Astellas presented encouraging survival data for PADCEV, in combination with pembrolizumab, for advanced bladder cancer. Pfizer also shared new findings on zolbetuximab in gastric cancer. The developments highlight the company’s oncology pipeline as a potential driver of future growth.
Pfizer also declared a quarterly dividend of $0.43 per share.